Clinical Trial

STOP HCC-GAAD-APAC-Thailand

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
Hepatocellular carcinoma (HCC) surveillance is frequently underutilized, and currently available biomarkers, such as alpha-fetoprotein (AFP), demonstrate suboptimal diagnostic performance. This prospective study aims to evaluate a simplified multivariate index, the GAAD score-comprising gender, age, alpha-fetoprotein (AFP), and protein induced by vitamin K absence or antagonist-II (PIVKA-II)-for its ability to improve the detection of hepatocellular carcinoma in patients with chronic liver disease. The study hypothesizes that incorporation of the GAAD score into standard HCC surveillance strategies will improve diagnostic performance compared with existing surveillance modalities alone and may provide evidence to support its inclusion in future clinical practice guidelines.
Trial Details
NCT Number NCT07319299
Lead Sponsor Mahidol University
Conditions Hepatecellular Carcinoma, Cirrhosis, HBV Infection
Enrollment 2,100 participants
Start Date 2025-02-02
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-06